



Express Mail Label No.: E2 946405942 US  
Date of Deposit: October 4, 2002

Attorney Docket No. 14445-501

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Chalifour *et al.*  
SERIAL NUMBER: 09/724,842 EXAMINER: Sharon L. Turner, Ph.D.  
FILING DATE: November 28, 2000 ART UNIT: 1647  
FOR: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S AND  
AMYLOID RELATED DISEASES

October 4, 2002  
Boston, Massachusetts

Commissioner for Patents  
Washington, D.C. 20231  
ATTN: Examiner Sharon Turner, Art Unit 1647

RECEIVED  
OCT 09 2002  
TECH CENTER 1600/2900  
201  
10/15/02

**RESPONSE TO THE COMMUNICATION MAILED 09/04/02**

In the Examiner's Communication mailed 09/04/02, the Examiner required clarification regarding a discrepancy between the sequences of SEQ ID NOs. 25-27 as listed in the Sequence Listing and the sequences in the specification as amended on June 21, 2002. The Examiner also communicated that Figures 1, 2, 3 and 7 refer to particular amino acids without reference to the appropriate residues and/or sequence identifiers.

In response to the Examiner's Communication mailed 09/04/02, applicants herein provide a corrected Sequence Listing in conformance with 37 C.F.R. 1.821(a)(1) and (a)(2). Applicants wish to clarify that the sequences of SEQ ID NOs. 25-27, both in the specification and in the enclosed Sequence Listing, now reference Glu (E) as the last amino acid recited in the sequence. Furthermore, applicants have amended the Figures 1, 2, 3 and 7 in red ink and amended the specification as set forth below to identify the appropriate residues and/or sequence identifiers in the figures. The enclosed amended figures are informal and formal figures will be submitted when obtained.

## AMENDMENTS

### *In the Specification:*

Please replace lines 17-21 at page 6, with the following rewritten lines:

*D'*  
--FIG. 1 illustrates the targeted sites for the antigenic fragments (SEQ ID NO:1);

FIG. 2 illustrates the effect of 1 mg/ml of antibodies raised against D and L forms of A $\beta$ (16-21) (SEQ ID NO:7) on fibrillogenesis;

FIG. 3 illustrates the effect of 0.5 mg/ml of antibodies raised against D and L forms of A $\beta$ (16-21) (SEQ ID NO:7) on fibrillogenesis;

Please replace lines 1-2 at page 7, with the following rewritten lines:

*D<sup>2</sup>*  
-- FIG. 7 illustrates the response of rabbits to KLH-conjugated all-L and all-D KLVFFA (SEQ ID NO:7).--

## REMARKS

In response to the Examiner's Communication mailed 09/04/02, a corrected Sequence Listing (in paper and CRF form) accompanies this response in which SEQ ID NOs: 25-27 have been corrected such that the last residue is Glu ("E" in amino acid single letter nomenclature). Additionally, the description of Figures 1, 2, 3 and 7 in the specification has been amended to refer to the appropriate residues and/or sequence identifiers and Figures 1, 2, 3 and 7 have been amended to include the appropriate SEQ ID NOs.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE".